For the quarter ending 2026-03-31, INBS made $1,060,802 in revenue. -$2,862,712 in net income. Net profit margin of -269.86%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 1,060,802 | 896,774 | 1,111,797 | 843,884 |
| Cost of revenue (exclusive of amortization shown separately below) | 525,421 | 437,035 | 593,506 | 508,307 |
| Gross profit | 535,381 | 459,739 | 518,291 | 335,577 |
| Government support income | 165,695 | 72,720 | 193,267 | 383,862 |
| Selling, general and administrative expenses | 2,458,605 | 2,337,041 | 2,659,824 | 2,883,275.5* |
| Development and regulatory approval expenses | 893,979 | 522,113 | 486,169 | 582,466 |
| Depreciation and amortization | 290,393 | 281,896 | 303,378 | 300,298 |
| Impairment of long-lived assets | 5,200 | 27,147 | 261,780 | 55,015.5* |
| Total operating expenses | 3,648,177 | 3,168,197 | 3,711,151 | 3,821,055 |
| Loss from operations | -2,947,101 | -2,635,738 | -2,999,593 | -3,101,616 |
| Interest expense | 4,241 | 56,209 | 3,903 | 10,061 |
| Realized foreign exchange loss (gain) | 32,258 | - | - | 3 |
| Fair value gain on revaluation of financial instrument | - | - | - | 0 |
| Interest income | 49,444 | 5,334 | 8,504 | 9,058 |
| Total other income (expense), net | 77,461 | -50,875 | 4,601 | -1,000 |
| Net loss | -2,869,640 | -2,686,613 | -2,994,992 | -3,102,616 |
| Net loss attributable to non-controlling interest | -6,928 | -9,023 | -11,986 | -12,512 |
| Net loss attributable to intelligent bio solutions inc | -2,862,712 | -2,677,590 | -2,983,006 | -3,090,104 |
| Basic EPS | -1.8 | -2.82 | -0.35 | -0.586 |
| Diluted EPS | -1.8 | -2.82 | -0.35 | -0.586 |
| Basic Average Shares | 1,594,496 | 950,829 | 8,546,934 | 5,273,643* |
| Diluted Average Shares | 1,594,496 | 950,829 | 8,546,934 | 5,273,643* |
INTELLIGENT BIO SOLUTIONS INC. (INBS)
INTELLIGENT BIO SOLUTIONS INC. (INBS)